Winmill & Co’s Moderna MRNA Stock Holding History

Winmill & Co’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-37,290	Closed	-$5.33M	–	78
2022 Q2	$5.33M	Buy	+37,290	New	+$5.33M	1.93%	17

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Winmill & Co's MRNA Position: Q3 2022 in Review

Winmill & Co sold out of Moderna (MRNA) in Q3 2022, closing a stake of 37,290 shares — an estimated $5.33M sold.

Winmill & Co first reported a position in MRNA in Q2 2022 and held it in 1 quarter. The position peaked at $5.33M in Q2 2022. 915 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

Winmill & Co reported no remaining Moderna position as of Q3 2022 after selling out during the quarter.
Winmill & Co sold 37,290 Moderna shares in Q3 2022, an estimated $5.33M.
Winmill & Co first reported a position in Moderna in Q2 2022 and held it in 1 quarter.
Winmill & Co's Moderna position peaked at $5.33M in Q2 2022.
915 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on Winmill & Co's 13F filing for Q3 2022, filed 10 Nov 2022.